Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
Suzanne Skoda-Smith, Troy R Torgerson, Hans D OchsSeattle Children’s Research Institute and Department of Pediatrics, University of Washington, Seattle, WashingtonAbstract: Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack...
Saved in:
Main Authors: | Suzanne Skoda-Smith (Author), Troy R Torgerson (Author), Hans D Ochs (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
by: Wood P
Published: (2012) -
An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
by: Pollock RF, et al.
Published: (2018) -
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
by: Mona Al-Ahmad, et al.
Published: (2017) -
Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013) -
Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024)